DUBLIN–(BUSINESS WIRE)–The "Rheumatoid Arthritis (RA) – Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical and forecasted RA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Rheumatoid Arthritis (RA) Understanding
Rheumatoid Arthritis Overview
Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease that is known to impact the joints of the body adversely. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body, on the onset of disease, the immune response primarily attacks and harm the joints. RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.
Clinically, the symptoms of RA significantly differ between early-stage RA and insufficiently treated later stages of the disease. Early-stage RA is characterized by generalized disease symptoms such as fatigue, flu-like feeling, swollen and tender joints, and morning stiffness; and is paralleled by elevated levels of C-reactive protein (CRP) and an increased erythrocyte sedimentation rate (ESR). In contrast, insufficiently treated RA displays a complex clinical picture with the occurrence of serious systemic manifestations such as pleural effusions, lung nodules and interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, keratoconjunctivitis, atherosclerosis, hematologic abnormalities (e.g., anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint misalignments, loss of range of motion, bone erosion, cartilage destruction, and rheumatic nodules. These systemic manifestations caused by the chronic inflammatory state in RA patients result in increased mortality.
Rheumatoid Arthritis Diagnosis
Typically, RA is diagnosed by a combination of patient's symptoms, results of doctors examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.
More than two thirds of RA patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.
The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA, Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- RA Epidemiology
Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.
- The United States, in 2017, accounted for 1,333,290 RA prevalent cases, which are expected to grow during the study period, i.e., 2017-2030.
- In the year 2017, the total prevalent cases of RA in EU5 were 1,956,920, which are expected to grow during the study period, i.e., 2017-2030.
- In the year 2017, the total prevalent cases of RA in Japan were 1,066,584, which are expected to grow during the study period, i.e., 2017-2030.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global RA market
- Quantify patient populations in the global RA market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for RA therapeutics in each of the markets covered
- Understand the magnitude of RA population by its severity
- The RA epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- The RA Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
- In 2017, the total diagnosed prevalent cases of RA in the 7MM were 3,825,649, which will probably rise during the study period, i.e., 2017-2030.
- In the 7MM, the total gender-specific prevalent cases of RA were 1,007,646 for males and 2,818,003 for females in the year 2017.
For more information about this report visit https://www.researchandmarkets.com/r/fxpicl
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900